These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29876019)

  • 1. Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines.
    Mazzuca F; Onesti CE; Roberto M; Di Girolamo M; Botticelli A; Begini P; Strigari L; Marchetti P; Muscaritoli M
    Oncotarget; 2018 May; 9(39):25714-25722. PubMed ID: 29876019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study.
    Maddalena C; Ponsiglione A; Camera L; Santarpia L; Pasanisi F; Bruzzese D; Panico C; Fiore G; Camardella S; Caramia T; Farinaro A; De Placido S; Carlomagno C
    World J Clin Oncol; 2021 May; 12(5):355-366. PubMed ID: 34131567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcopenia as a risk factor of severe laboratory adverse events in breast cancer patients receiving perioperative epirubicin plus cyclophosphamide therapy.
    Ueno A; Yamaguchi K; Sudo M; Imai S
    Support Care Cancer; 2020 Sep; 28(9):4249-4254. PubMed ID: 31900607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer.
    Rimar KJ; Glaser AP; Kundu S; Schaeffer EM; Meeks J; Psutka SP
    Bladder Cancer; 2018 Oct; 4(4):411-418. PubMed ID: 30417052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
    Prado CM; Baracos VE; McCargar LJ; Reiman T; Mourtzakis M; Tonkin K; Mackey JR; Koski S; Pituskin E; Sawyer MB
    Clin Cancer Res; 2009 Apr; 15(8):2920-6. PubMed ID: 19351764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
    Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
    Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial.
    Delrieu L; Martin A; Touillaud M; Pérol O; Morelle M; Febvey-Combes O; Freyssenet D; Friedenreich C; Dufresne A; Bachelot T; Heudel PE; Trédan O; Crochet H; Bouhamama A; Pilleul F; Pialoux V; Fervers B
    Breast Cancer Res Treat; 2021 Aug; 188(3):601-613. PubMed ID: 34013451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of body composition parameters on severe toxicities in patients with locoregionally advanced nasopharyngeal carcinoma undergoing neoadjuvant chemotherapy.
    Xing X; Zhou X; Yang Y; Li Y; Hu C; Shen C
    Ann Transl Med; 2021 Jul; 9(14):1180. PubMed ID: 34430621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane-Based Chemotherapy for Early-Stage Breast Cancer.
    Shachar SS; Deal AM; Weinberg M; Williams GR; Nyrop KA; Popuri K; Choi SK; Muss HB
    Clin Cancer Res; 2017 Jul; 23(14):3537-3543. PubMed ID: 28143874
    [No Abstract]   [Full Text] [Related]  

  • 10. Body composition change during neoadjuvant chemotherapy for breast cancer.
    Jang MK; Park S; Park C; Doorenbos AZ; Go J; Kim S
    Front Oncol; 2022; 12():941496. PubMed ID: 36091109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining reference values for low skeletal muscle index at the L3 vertebra level based on computed tomography in healthy adults: A multicentre study.
    Kong M; Geng N; Zhou Y; Lin N; Song W; Xu M; Li S; Piao Y; Han Z; Guo R; Yang C; Luo N; Wang Z; Jiang M; Wang L; Qiu W; Li J; Shi D; Li R; Cheung EC; Chen Y; Duan Z
    Clin Nutr; 2022 Feb; 41(2):396-404. PubMed ID: 34999334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
    Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
    Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
    Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
    Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
    Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of muscle mass in the legs of patients with peripheral arterial occlusive disease: associations between volumetric and cross-sectional single-slice measurements for identification of atrophy and focal sarcopenia.
    Ma KF; Berends B; Vedder IR; Levolger S; Gupta M; Schuurmann RC; de Vries JPPM; Bokkers RP
    J Cardiovasc Surg (Torino); 2019 Dec; 60(6):672-678. PubMed ID: 31603293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma.
    Iritani S; Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Suetsugu A; Shiraki M; Shimizu M; Moriwaki H
    J Gastroenterol; 2015 Mar; 50(3):323-32. PubMed ID: 24817668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
    Griffin OM; Duggan SN; Ryan R; McDermott R; Geoghegan J; Conlon KC
    Pancreatology; 2019 Sep; 19(6):850-857. PubMed ID: 31362865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.
    Anandavadivelan P; Brismar TB; Nilsson M; Johar AM; Martin L
    Clin Nutr; 2016 Jun; 35(3):724-30. PubMed ID: 26065721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT-Determined Sarcopenia in GLIM-Defined Malnutrition and Prediction of 6-Month Mortality in Cancer Inpatients.
    Sánchez-Torralvo FJ; Ruiz-García I; Contreras-Bolívar V; González-Almendros I; Ruiz-Vico M; Abuín-Fernández J; Barrios M; Alba E; Olveira G
    Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.